FDA Targets Online Pharmacy for Unapproved, Misbranded Drug Sales

Another internet-based pharmacy has drawn FDA enforcement action for selling unapproved and misbranded drugs to U.S. consumers — a signal that the agency is intensifying scrutiny of online channels operating outside federal approval and labeling requirements. Why this matters: For legitimate manufacturers and compounders, each new warning letter reinforces the compliance boundaries around drug approval under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and proper labeling under 21 CFR Part 211. Facilities that distribute finished dosage forms — whether through brick-and-mortar or digital storefronts — must ensure every product in commerce carries an approved NDA or ANDA, or falls within a recognized exemption such as 503A or 503B compounding.

On April 1, 2026, FDA issued a warning letter to Dry Springs Pharmacy citing the unlawful sale of unapproved and misbranded drugs to United States consumers over the internet. The letter, published on FDA's Inspections, Compliance, Enforcement, and Criminal Investigations page on April 14, 2026, identifies violations that place the firm's products outside the scope of lawful distribution. Under the FD&C Act, a drug is deemed "unapproved" when it is introduced into interstate commerce without an effective FDA approval, and "misbranded" when its labeling fails to bear adequate directions for use or otherwise does not comply with statutory requirements.

The enforcement action fits a broader pattern. FDA has steadily expanded its surveillance of internet-based drug sellers, particularly those marketing products directly to consumers without the safeguards embedded in the approved-drug framework — including GMP manufacturing controls, validated processes, and compliant labeling. For QA directors and regulatory affairs leads, the takeaway is straightforward: digital distribution does not exempt a product from the same approval, labeling, and current good manufacturing practice (cGMP) obligations that apply to any other channel. Firms engaged in compounding should verify that their operations satisfy the conditions of either Section 503A (patient-specific prescriptions) or Section 503B (outsourcing facilities registered with FDA), as products falling outside these frameworks are treated as unapproved new drugs.

Plant heads and quality leaders should use this case as a prompt for internal review. Key questions include: Are all products currently in distribution covered by an approved application or a valid compounding exemption? Does labeling meet 21 CFR Part 201 requirements? Are internet sales channels — including third-party platforms — inventoried and assessed for compliance risk? FDA's willingness to issue public warning letters for online sales underscores that enforcement extends to every point in the supply chain where a product reaches the end user.

Source: FDA Warning Letter to Dry Springs Pharmacy (723460), dated April 1, 2026, published April 14, 2026. Available at FDA.gov.